Literature DB >> 9426407

MUC2 gene suppression in human colorectal carcinomas and their metastases: in vitro evidence of the modulatory role of DNA methylation.

C Hanski1, E Riede, A Gratchev, H D Foss, C Böhm, E Klussmann, M Hummel, B Mann, H J Buhr, H Stein, Y S Kim, J Gum, E O Riecken.   

Abstract

The development of the majority of colorectal carcinomas is associated with a diminished expression of the intestinal mucin MUC2 in the tumor cells. The significance and the mechanism of this alteration are not yet known. We sought to determine the molecular basis of this tumor-associated change and to investigate the extent to which it might also relate to metastases. MUC2 gene expression was compared in normal (N), carcinomatous (T), and metastatic tissues (M) from nine patients by immunohistochemistry, in situ hybridization, and Northern blotting. Immunohistochemistry and in situ hybridization showed consistently lower amounts of the expressed protein and mRNA in T and in M than in N; quantitative analysis by Northern blotting confirmed that the differences between MUC2 mRNA expression between N, T, and M were significant, the expression in metastases being less than 5% of that in the normal colonic tissue. The influence of DNA methylation as a possible regulatory mechanism of MUC2 gene expression was tested after the 5' and 3'-regions flanking the first exon of MUC2 were recovered from a genomic DNA library and used as probes in Southern blot. The DNA was isolated from colon carcinoma cell lines expressing MUC2 strongly (LS174T) or moderately (T84) and from that which was nonexpressing (Colo 205), and it was digested with the methylation-sensitive enzyme HpaII. The Southern blot patterns indicated that the increased methylation in the promoter region was concomitant with the decrease of MUC2 mRNA expression. Methylation of the promoter region ligated into a reporter vector suppressed the expression of the luciferase reporter gene in the three investigated cell lines. Furthermore, the expression of MUC2 gene was enhanced by treating the MUC2-expressing colon carcinoma cells with 5-aza-2'-deoxycytidine, a methylation-inhibiting agent. To our knowledge this is the first report to show that: (a) MUC2 gene is strongly suppressed in liver and lymph node metastases of colorectal carcinomas, and (b) suppression of MUC2 gene in colon carcinoma cells in vitro is associated with methylation of the promoter region.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9426407

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  18 in total

Review 1.  Mucins and mucosal protection in the gastrointestinal tract: new prospects for mucins in the pathology of gastrointestinal disease.

Authors:  A P Corfield; N Myerscough; R Longman; P Sylvester; S Arul; M Pignatelli
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

Review 2.  Regulation of airway mucin gene expression.

Authors:  Philip Thai; Artem Loukoianov; Shinichiro Wachi; Reen Wu
Journal:  Annu Rev Physiol       Date:  2008       Impact factor: 19.318

3.  Poorly differentiated adenocarcinoma of the colon: subsite location and clinicopathologic features.

Authors:  Yasuo Imai
Journal:  Int J Colorectal Dis       Date:  2014-11-23       Impact factor: 2.571

Review 4.  Pathogenesis of human enterovirulent bacteria: lessons from cultured, fully differentiated human colon cancer cell lines.

Authors:  Vanessa Liévin-Le Moal; Alain L Servin
Journal:  Microbiol Mol Biol Rev       Date:  2013-09       Impact factor: 11.056

5.  Mucins in neoplastic spectrum of colorectal polyps: can they provide predictions?

Authors:  Mahsa Molaei; Babak Khoshkrood Mansoori; Reza Mashayekhi; Mohsen Vahedi; Mohamad Amin Pourhoseingholi; Seyed Reza Fatemi; Mohammad Reza Zali
Journal:  BMC Cancer       Date:  2010-10-07       Impact factor: 4.430

Review 6.  MUC1 and MUC2 in pancreatic neoplasia.

Authors:  E Levi; D S Klimstra; A Andea; O Basturk; N V Adsay
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

Review 7.  Clinicopathological utility of sialoglycoconjugates in diagnosing and treating colorectal cancer.

Authors:  Yoshinori Inagaki; Jianjun Gao; Peipei Song; Norihiro Kokudo; Munehiro Nakata; Wei Tang
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

8.  Loss of MUC2 expression predicts disease recurrence and poor outcome in colorectal carcinoma.

Authors:  Adam Elzagheid; Fatma Emaetig; Abdelbaset Buhmeida; Matti Laato; Omran El-Faitori; Kari Syrjänen; Yrjö Collan; Seppo Pyrhönen
Journal:  Tumour Biol       Date:  2012-11-21

9.  Differential mucin phenotypes and their significance in a variation of colorectal carcinoma.

Authors:  Yasuo Imai; Hidetsugu Yamagishi; Kazunori Fukuda; Yuko Ono; Tohru Inoue; Yoshihiko Ueda
Journal:  World J Gastroenterol       Date:  2013-07-07       Impact factor: 5.742

10.  CpG-island methylation of the ER promoter in colorectal cancer: analysis of micrometastases in lymph nodes from UICC stage I and II patients.

Authors:  J Harder; V Engelstaedter; H Usadel; S Lassmann; M Werner; P Baier; F Otto; M Varbanova; E Schaeffner; M Olschewski; H E Blum; O G Opitz
Journal:  Br J Cancer       Date:  2009-01-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.